Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:41:45.212Z.
Calculation as of: 2026-10-06T15:41:45.212Z.
Quote observation: 2026-10-06T15:39:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ff4a69d5e0bd829addfa263bba904bf87580f902e4d2830b11cef9910c58a28
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$130.42M
Price/FCF Ratio
9.99
TTM Avg
13.06
3Y Avg
13.06
5Y Avg
13.06
Market Cap
$125.34M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $127.66M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.42M | 9.99 | 13.06 | 13.06 | 13.06 |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $123.17M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $132.37M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $134.69M | N/A | 63.37 | 576.34 | 569.67 |
| Freenome, Inc. (FRNM)vs › | $136.39M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.38M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
